We analyzed the antibiotic susceptibility of 5,348 urinary isolates of Escherichia coli, "Kiebsiella aerogenes,"
and Proteus mirbilis grown in three laboratories from 1980 to 1985. A continuous rise in resistance to trimethoprim-sulfamethoxazole was observed; 63% of the strains from inpatients in 1984 and 51% of those from outpatients in 1985 were resistant to this drug. Isolates from outpatients in 1985 were mostly susceptible to nitrofurantoin (mean susceptibility, 92%) and to oral cephalosporins (mean susceptibility, 84%). As for isolates from inpatients, none of the antimicrobial agents now used was satisfactory for initial chemotherapy, indicating a need for new antibacterial strategies.
With the introduction of trimethoprim-sulfamethoxazole (TMP-SMX), which acts synergistically on bacterial folic acid synthesis (2, 7) , it was believed that the development of resistance among bacterial species susceptible to the combination was highly unlikely, because it would require two independent mutational events (14) . The same speculation also applied to the acquisition of plasmid-mediated resistance (13) . During the last 15 years, TMP-SMX has been regarded as the first-line drug for the curative and prophylactic management of patients with urinary tract infection (UTI; 6, 15, 18, 19) , and indeed it has been the initial therapeutic agent in over 91% of our patients. However, by 1972 Lacey et al. (9) had already found a 2.5% incidence of resistance to TMP among urinary bacterial isolates, and later Freuensgaard and Komer (5) and Huovinen and Toivanen (8) reported increasing resistance, up to 30.1%, to TMP or TMP-SMX. In 1982, Murray et al. (14) reported a high incidence of resistance to TMP-SMX among fecal enterobacteria, particularly Escherichia coli strains isolated during a diarrhea prevention study.
In view of these data and with our clinical impression that the rate of urinary bacterial isolates resistant to TMP-SMX is gradually increasing, this study was conducted to try to answer the following questions. ( tively. The organisms were tested for susceptibility to TMP-SMX, ampicillin, cephalosporins, and nitrofurantoin during the whole period and were also tested for susceptibility to gentamicin in 1984. Pseudomonas aeruginosa and other bacteria isolated mainly in laboratories B and C from hospitalized patients with complicated UTI were examined for susceptibility to gentamicin, in view of their already wellrecognized high resistance to TMP-SMX, ampicillin, and nitrofurantoin (4, 6, 8, 18) .
Antimicrobial susceptibility was assessed by the disk diffusion technique with commercially obtained disks according to National Committee for Clinical Laboratory Standards performance standards (14a). The recommended media and standard control strains were used by all three laboratories. Quality control test results remained within a similar zone diameter range throughout the study. The zone diameter interpretative standards for resistance to TMP-SMX, ampicillin, cephalothin, nitrofurantoin, and gentamicin were, respectively, '10, <11, s14, s14, and s12 mm. Otherwise, the organism was designated as being susceptible to the antimicrobial agent tested.
The bacteriological findings and the rates of bacterial susceptibility to antimicrobial agents are shown in Tables 1  and 2. A total of 5,348 E. coli, "K. aerogenes," and P. mirabilis isolates were examined. In all three laboratories, a gradual increase in bacterial resistance to TMP-SMX was observed. The trend toward development of E. coli resistance to TMP-SMX in the outpatient laboratory (laboratory A) lagged behind that of the two medical centers (laboratories B and C) by about 1 year; the incidence of resistant E. coli was 56 and 48% in laboratories B and C in 1984 and 52% in laboratory A in 1985.
Bacterial resistance to ampicillin in laboratories B and C was already high for all three bacteria in 1980 and remained more or less the same during 1982 and 1984. In laboratory A, the rates of ampicillin resistance observed in 1985 were simiilar to those observed among inpatients.
No significant changes in bacterial susceptibility to cephalosporins and nitrofurantoin were noted over the period studied. For cephalosporins, susceptibility rates were better in strains from outpatients than in strains from inpatients: (11) , and 20.3 to 39.8%, in 1980 (8) . Such rates of resistance 86% of E. coli isolates from outpatients in 1985 versus 66 and toward TMP-SMX were also found (8) . As observed also by 75% from inpatient isolates in 1984. For nitrofurantoin, the others (1, 4, 8) , we found that bacteria isolated from inpatisusceptibility rates of E. coli were similar in all three ents generally showed a higher incidence of resistance as laboratories over the whole period (89 to 99%). For "K. compared with those isolated at the same time from outpaaerogenes" and P. mirabilis, susceptibility to nitrofurantoin tients. In our series, it sometimes took only 1 year for E. coli was found to be satisfactory in laboratories A and C but low strains isolated from outpatients to gain the same degree of in laboratory B.
resistance to TMP-SMX as isolates from inpatients (Table   Bacterial susceptibility to gentamicin was studied in 1984
2). Such a rapid decline in bacterial susceptibility to TMPin laboratories B and C. The susceptibility rates of E. coli SMX might be partly the result of the popularity and were 90.5 and 91%, the susceptibility rates of P. mirabilis promiscuous use of the medication (4, 11, 16, 18) . were 81 and 83%, and the susceptibility rates of "K. aeroThe choice of antimicrobial agent for the initial treatment genes" were 86 and 85%; for all three organisms combined, of uncomplicated UTIs in outpatients should be derived the susceptibility rates were 85 and 84% in laboratories B from knowledge of the antimicrobial susceptibility status of and C, respectively. In 1984, susceptibilities to gentamicin E. coli, "K. aerogenes," and P. mirabilis, which are responwere also examined in 244 isolates of P. aeruginosa, Enterosible for most of the infections in this population (8, 20) . bacter aerogenes, Staphylococcus epidermidis, StreptococPractically, it can rely on the antibiotic susceptibility of E. cus faecalis, and others at laboratories B and C and were coli alone, because this organism constitutes 82.2 to 84.2% found to be 68 and 61%, respectively. of the common uropathogens isolated from outpatients (TaOur study showed a progressive increase in the incidence ble 1), and the combined mean antimicrobial susceptibility of of resistance of the common bacterial uropathogens to all three common uropathogens thus mostly conforms with TMP-SMX, from 46% (in 1980) to 63% (in 1984) in isolates that of E. coli alone ( Table 2 ). According to our data, among obtained from inpatients and from 27% (in 1981) to 51% (in the commonly administered antimicrobial agents, nitrofuran-1985) in those obtained from outpatients (Table 2) . This toin appears to be the best choice, with 92% of E. coli strains trend can also be discerned from reports published during being susceptible to this drug. Second best would be oral the last 15 years showing a 2.5% incidence of resistance to cephalosporins, to which 84% of the E. coli strains were TMP in urine bacterial isolates, in 1972 (9), 13.2%, in 1977 susceptible (Table 2) . On the other hand, susceptibility to VOL. 31, 1987 cephalosporins was low among the isolates from inpatients, and a further decrease in susceptibility to these drugs is also soon to be expected among isolates from outpatients. With regard to isolates from inpatients, all three organisms exhibited high or moderate resistance to all four antimicrobial agents tested; only E. coli showed good susceptibility to nitrofurantoin. The combined susceptibility of E. coli, "K. aerogenes," and P. mirabilis to gentamicin was 84 to 85%. However, in hospitalized patients with complicated urinary conditions, infections are frequently caused by other bacteria, such as P. aeruginosa, E. aerogenes, S. epidermidis, and S. faecalis, whose susceptibility to gentamicin in our series was only 61 to 68%. Gentamicin alone thus would not be sufficient as the initial treatment for inpatients with UTI, and a combination of drugs is necessary. According to our data, the best such combination is gentamicin and cephalosporins, although a continuous and unrestricted use of these medications would increase the incidence of resistant strains, whereas a temporary reduction in the use of gentamicin may reduce the rate of bacterial resistance to the drug (10, 17 ). There appears to be a need to introduce new modes of therapy for UTIs, e.g., amoxicillin-clavulanic acid in outpatients (3, 12) and broad-spectrum cephalosporins, new aminoglycosides, and extended-spectrum ureido penicillins in inpatients and subjects with complicated infections (10, 15, 17) .
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